The Role of Immunotherapy in Pancreatic Cancer

被引：60

作者：

Mukherji, Reetu ^{[1
]}

Debnath, Dipanjan ^{[2
]}

Hartley, Marion L. ^{[1
]}

Noel, Marcus S. ^{[1
]}

机构：

[1] Medstar Georgetown Univ Hosp, Div Hematol & Oncol, Ruesch Ctr Cure Gastrointestinal Canc, Georgetown Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA

[2] Medstar Washington Hosp Ctr, Dept Internal Med, 110 Irving St NW, Washington, DC 20010 USA

来源：

CURRENT ONCOLOGY | 2022年 / 29卷 / 10期

关键词：

immunotherapy; PD-1; PD-L1; pancreas cancer; adenocarcinoma; checkpoint inhibitor; vaccine; COLONY-STIMULATING FACTOR; CAR T-CELLS; RAS PEPTIDE VACCINATION; SECRETING TUMOR VACCINE; RANDOMIZED PHASE-II; OPEN-LABEL; NAB-PACLITAXEL; GASTROESOPHAGEAL JUNCTION; DUCTAL ADENOCARCINOMA; CHECKPOINT BLOCKADE;

D O I：

10.3390/curroncol29100541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients.

引用

页码：6864 / 6892

页数：29

共 166 条

[1] A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer [J].

Aglietta, M. ;

Barone, C. ;

Sawyer, M. B. ;

Moore, M. J. ;

Miller, W. H., Jr. ;

Bagala, C. ;

Colombi, F. ;

Cagnazzo, C. ;

Gioeni, L. ;

Wang, E. ;

Huang, B. ;

Fly, K. D. ;

Leone, F. .

ANNALS OF ONCOLOGY, 2014, 25 (09) :1750-1755

[2] Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer [J].

Aida, Kouichirou ;

Miyakawa, Reina ;

Suzuki, Koji ;

Narumi, Kenta ;

Udagawa, Takeshi ;

Yamamoto, Yuki ;

Chikaraishi, Tatsuya ;

Yoshida, Teruhiko ;

Aoki, Kazunori .

CANCER SCIENCE, 2014, 105 (02) :159-167

[3] A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers [J].

Algaze, Sandra ;

Hanna, Diana L. ;

Azad, Nilofer Saba ;

Thomas, Jacob Stephen ;

Iqbal, Syma ;

Habib, Diane ;

Ning, Yan ;

Barzi, Afsaneh ;

Patel, Ronak ;

Lenz, Heinz-Josef ;

El-Khoueiry, Anthony B. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[4] Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. [J].

Amaria, Rodabe Navroze ;

Bernatchez, Chantale ;

Forget, Marie-Andree ;

Haymaker, Cara L. ;

Conley, Anthony Paul ;

Livingston, J. Andrew ;

Varadhachary, Gauri Rajani ;

Javle, Milind M. ;

Maitra, Anirban ;

Tzeng, Ching-Wei David ;

Hinchcliff, Emily ;

Bayer, Virginia ;

Gasior, Yvonne ;

Hilton, Tyler ;

Celestino, Joseph ;

Rangel, Kelly M. ;

Yuan, Ying ;

Lu, Karen H. ;

Hwu, Patrick ;

Jazaeri, Amir A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[5] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[6]

[Anonymous], 2021, NCCN Guidelines Version 1.2022 Non-Small Cell Lung Cancer

[7]

[Anonymous], 2021, Cancer Stat Facts: Pancreatic Cancer

[8] Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells [J].

Anurathapan, Usanarat ;

Chan, Robert C. ;

Hindi, Hakeem F. ;

Mucharla, Roopa ;

Bajgain, Pradip ;

Hayes, Brendan C. ;

Fisher, William E. ;

Heslop, Helen E. ;

Rooney, Cliona M. ;

Brenner, Malcolm K. ;

Leen, Ann M. ;

Vera, Juan F. .

MOLECULAR THERAPY, 2014, 22 (03) :623-633

[9]

Argani P, 2001, CANCER RES, V61, P4320

[10] Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer [J].

Asahara, Shingo ;

Takeda, Kazuyoshi ;

Yamao, Kenji ;

Maguchi, Hiroyuki ;

Yamaue, Hiroki .

JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11

← 1 2 3 4 5 6 7 8 9 10 →